PhD, BSc (Hons)
Divisional Safety Officer and Facilities Manager for NDCLS
I am a Postdoctoral researcher with a strong background in antibody development and use.
I have previously worked on the preclinical development of therapeutic antibodies for a variety of cancer indications, but I am currently investigating the role of the FOXP family of transcription factors in haematological malignancies, in particular diffuse large B-cell lymphoma (DLBCL), with a view to improving treatment options for patients. DLBCL is the most common type of B-cell lymphoma and outcomes for patients who fail to respond to current treatment options is poor.
A number of subtypes of DLBCL have been identified including a poor prognosis type with an activated B-cell (ABC)-like gene expression signature.
I am using CRISPR/Cas9 technology to identify regulators of FOXP1 expression in this aggressive subtype to identify novel targets for therapy. My work uses a wide range of techniques across the disciplines of molecular biology, biochemistry and cell biology, but I have a particular expertise in antibody production and validation, and in histological and immunohistochemical methods.
Outside of my research, I am also the Deputy Divisional Safety Officer for NDCLS.
Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201.
Trenevska I. et al, (2021), PLoS One, 16
CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.
Felce SL. et al, (2020), Front Oncol, 10
Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.
Ait-Tahar K. et al, (2017), Adv Hematol, 2017